Q2 2021 Photocure ASA Earnings Call Transcript
All right. Well, welcome. This is Dan Schneider, President and CEO of Photocure. With me today is Erik Dahl, CFO, and you've plugged into the Photocure results for second quarter 2021.
Next slide. Just reminder, disclaimers are in fact for today's presentation. Next slide. Top line second quarter highlights. We've had progress in both commercial regions despite the continued pandemic, COVID-19. We had 66% revenue growth in the second quarter. That's 87% positive constant currency. EBITDA of positive NOK 5.8 million. We also had 3 key study publications. One of them actually emanating from our own U.S. registry, which is fantastic. And partnership activities continue with Asieris dosing the first patient for Cevira in Europe, [pivots] Phase III trial. And Genotests in Chile filed its MAA on a fast track review and expect more information as time goes on.
Next slide. I'd like to give you a really quick COVID-19 update. Access restrictions continued due to the third and fourth waves. We're now entering into the delta wave, unfortunately
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
